Aisling Capital

General contacts

Investor type

PE / VC

Founded

2000

AUM

$1 800 M

Location

New York, New York, United States

Investment Ticket

$10-50 m

Investment Stage

Series B Series A Seed Late Stage (Series C+)

Region of investment

North America Europe

Investor profile last updated: 16 August, 2026

Profile

Aisling Capital is an investment firm based in New York, founded in 2000. It focuses on investing in companies that develop and commercialize innovative healthcare products, services, and technologies. The firm is staffed by a team of eight investment professionals who possess a combined 150+ years of experience in the healthcare industry. Aisling Capital distinguishes itself by leveraging its clinical, operational, and financial expertise to support the growth and success of its portfolio companies.

The firm invests in a range of healthcare sectors including life sciences, targeting unmet medical needs through private and public companies. Investment structures employed by Aisling Capital include seed and venture financings for development-stage companies, as well as small-cap publicly traded equities, structured debt, royalty deals, and large-cap leveraged buyouts of profitable companies. Aisling Capital has raised over $1.8 billion in committed capital across five funds since its inception.

Notable companies in Aisling Capital's portfolio include Quintiles, the largest provider of biopharmaceutical development services, Loxo, a company developing selective medicines for genomically defined cancers, and Zeltiq, known for their CoolSculpting® fat reduction technology. Other notable investments include Biohaven, T2 Biosystems, Harmony, and Aimmune, which are focused on innovative treatments and technologies in healthcare.

Industry

Biotechnology Fashion/Beauty Financial Services Fintech Food and Beverage Healthcare Services Medical Devices Pharmaceuticals MedTech Technology Life Sciences HealthTech

Aisling Capital Funds

Name	Type	Industry	Stage	Region	Size	AUM	Launch date
Aisling Capital IV	Venture Capital (VC)	Healthcare Services Medical Devices Life Sciences	Seed Series A	North America	$5-10 m	$280 M	November 2017
Aisling Capital Fund V	Venture Capital (VC)	Healthcare Services Medical Devices Life Sciences	Seed Series A	North America	$5-10 m	$144 M	June 2020
Aisling Capital I, L.P.	Venture Capital (VC)	Biotechnology Healthcare Services Medical Devices Pharmaceuticals Life Sciences	Pre-seed Seed	North America	$5-10 m	$30 M	January 2013
Aisling Capital II	Venture Capital (VC)	Biotechnology Healthcare Services Medical Devices Pharmaceuticals Life Sciences	Pre-seed Seed	North America	$5-10 m	$550 M	August 2015

Contacts

Name

Title

Social Networks

Eric Aguiar Partner

Partner

e•••@•••

Aftab Kherani Operating Partner

Operating Partner

a•••@•••

Upgrade to see contacts

F70E3pOGS2658nbC F70E3pOGS2658nbC

F70E3pOGS2658nbC

[email protected]

F70E3pOGS2658nbC F70E3pOGS2658nbC

F70E3pOGS2658nbC

[email protected]

F70E3pOGS2658nbC F70E3pOGS2658nbC

F70E3pOGS2658nbC

[email protected]

Investment-team contacts for Aisling Capital — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.

Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about Aisling Capital

Is Aisling Capital a venture capital or private equity firm?

Aisling Capital is a venture capital and private equity firm. It backs companies at Series B, Series A, Seed and Late Stage (Series C+), writing tickets of $10-50 m.

Where is Aisling Capital located?

Aisling Capital is located in New York, New York, United States.

When was Aisling Capital founded?

Aisling Capital was founded in 2000.

What sectors and industries does Aisling Capital invest in?

Aisling Capital invests in companies and startups in Biotechnology, Fashion/Beauty, Financial Services, Fintech, Food and Beverage, Healthcare Services, Medical Devices, Pharmaceuticals, MedTech, Technology, Life Sciences, HealthTech.

What is Aisling Capital geographical focus of investments?

Aisling Capital invests in companies and startups in North America, Europe.

At what stages of companies and startups does Aisling Capital typically invest in?

Aisling Capital invests in companies and startups at Series B, Series A, Seed, Late Stage (Series C+).

What is the usual amount of Aisling Capital investment?

Aisling Capital usually invests $10-50 m on average.

What is the amount of assets of under management (AUM) for Aisling Capital?

Aisling Capital has around $1 800m assets under management.

When was Aisling Capital last fund created?

Aisling Capital last fund was created/launched in 2020-06-26

What are the contacts of Aisling Capital?

Aisling Capital can be reached through its website aislingcapital.com, its LinkedIn page and its X account. Its general enquiries address is [email protected]. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for Aisling Capital — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

Can I access Aisling Capital data via API or MCP?

Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query Aisling Capital directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.

When was the Aisling Capital profile last updated?

Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 16 August, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.